Tela Bio price target lowered to $15 from $20 at Piper Sandler

Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Tela Bio to $15 from $20 but keeps an Overweight rating on the shares. The analyst notes that his price target cut is due to the moderated pace of revenue growth in the near term, though he remains impressed by the top-line growth of this company even in early adoption stages of the technology. O’Brien added that he continues to believe that when pandemic-related pressures subside, Tela Bio’s top-line "growth dam will burst" and produce "standout performance" relative to many other small cap med tech names.